Country: Evrópusambandið
Tungumál: enska
Heimild: EMA (European Medicines Agency)
nitisinone
Cycle Pharmaceuticals (Europe) Ltd
A16AX04
nitisinone
Other alimentary tract and metabolism products,
Tyrosinemias
Treatment of adult and paediatric patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.
Revision: 5
Authorised
2018-07-26
18 B. PACKAGE LEAFLET 19 PACKAGE LEAFLET: INFORMATION FOR THE USER NITYR 10 MG TABLETS nitisinone READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Nityr is and what it is used for 2. What you need to know before you take Nityr 3. How to take Nityr 4. Possible side effects 5. How to store Nityr 6. Contents of the pack and other information 1. WHAT NITYR IS AND WHAT IT IS USED FOR Nityr contains the active substance nitisinone. Nityr is used to treat: - A rare disease called hereditary tyrosinemia type 1 in adults, adolescents and children. - A rare disease called alkaptonuria (AKU) in adults. In these diseases your body is unable to completely break down the amino acid tyrosine (amino acids are building blocks of our proteins), forming harmful substances. These substances are accumulated in your body. Nityr blocks the breakdown of tyrosine and the harmful substances are not formed. For the treatment of hereditary tyrosinemia type 1, you must follow a special diet while you are taking this medicine, because tyrosine will remain in your body. This special diet is based on low tyrosine and phenylalanine (another amino acid) content. For the treatment of AKU, your doctor may advise you to follow a special diet. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE NITYR _ _ DO NOT TAKE NITYR - if you are allergic to nitisinone or any of the other ingredients of this medicine (listed in section 6). Do not breast-feed while taking this medicine, see section “Pregnancy and breast-feeding”. WARNINGS Lestu allt skjalið
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Nityr 10 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10 mg nitisinone. Excipient with known effect Each tablet contains 102.99 mg lactose (as monohydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet. White to beige, round (7 mm), flat tablet, which may display light yellow to brown speckles, marked “10” on one side and “L” on the other side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Hereditary tyrosinemia type 1 (HT-1) Nityr is indicated for the treatment of adult and paediatric patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. Alkaptonuria (AKU) Nityr is indicated for the treatment of adult patients with alkaptonuria (AKU). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _HT-1_ Nitisinone treatment should be initiated and supervised by a physician experienced in the treatment of HT-1 patients. Treatment of all genotypes of the disease should be initiated as early as possible to increase overall survival and avoid complications such as liver failure, liver cancer and renal disease. Adjunct to the nitisinone treatment, a diet deficient in phenylalanine and tyrosine is required and should be followed by monitoring of plasma amino acids (see sections 4.4 and 4.8). _Starting dose HT-1 _ The recommended initial daily dose in the paediatric and adult population is 1 mg/kg body weight administered orally. The dose of nitisinone should be adjusted individually. It is recommended to administer the dose once daily. However, due to the limited data in patients with body weight < 20 kg, 3 it is recommended to divide the total daily dose into two daily administrations in this patient population. _Dose adjustment HT-1 _ During regular monitoring, it is appropriate to follow urine succinylacetone, liver function test values and alpha-fetoprotein levels (see section 4. Lestu allt skjalið